drugset / Trial / NCT06505395

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

NCT06505395

Phase 2 Recruiting 90 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.

Timeline

Start
2024-07-30
Primary completion
2027-08-01
Completion
2028-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Octreotide Peptide Intramuscular
Subject SYHX2008 Unknown Subcutaneous